Literature DB >> 12558458

Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Mark E Rupp1, Paul D Fey.   

Abstract

Extended spectrum beta-lactamase (ESBL)-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery scientists. ESBLs are enzymes capable of hydrolysing penicillins, broad-spectrum cephalosporins and monobactams, and are generally derived from TEM and SHV-type enzymes. ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. Although the prevalence of ESBLs is not known, it is clearly increasing, and in many parts of the world 10-40% of strains of Escherichia coli and Klebsiella pneumoniae express ESBLs. ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world and pose challenging infection control issues. Clinical outcomes data indicate that ESBLs are clinically significant and, when detected, indicate the need for the use of appropriate antibacterial agents. Unfortunately, the laboratory detection of ESBLs can be complex and, at times, misleading. Antibacterial choice is often complicated by multi-resistance. Many ESBL-producing organisms also express AmpC beta-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. In addition, there is an increasing association between ESBL production and fluoroquinolone resistance. Although in in vitro tests ESBLs are inhibited by beta-lactamase inhibitors such as clavulanic acid, the activity of beta-lactam/beta-lactamase inhibitor combination agents is influenced by the bacterial inoculum, dose administration regimen and specific type of ESBL present. Currently, carbapenems are regarded as the drugs of choice for treatment of infections caused by ESBL-producing organisms. Unfortunately, use of carbapenems has been associated with the emergence of carbapenem-resistant bacterial species such as Stenotrophomonas sp. or Pseudomonas sp.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558458     DOI: 10.2165/00003495-200363040-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  95 in total

1.  TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient.

Authors:  H Marchandin; C Carriere; D Sirot; H J Pierre; H Darbas
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Multiresistant Klebsiella pneumoniae in a neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaks.

Authors:  Y M Coovadia; A P Johnson; R H Bhana; G R Hutchinson; R C George; I E Hafferjee
Journal:  J Hosp Infect       Date:  1992-11       Impact factor: 3.926

3.  Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.

Authors:  L B Rice; J D Yao; K Klimm; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 4.  An outbreak of extended-spectrum, beta-lactamase-producing Salmonella senftenberg in a burns ward.

Authors:  G Revathi; K P Shannon; P D Stapleton; B K Jain; G L French
Journal:  J Hosp Infect       Date:  1998-12       Impact factor: 3.926

5.  Concurrent outbreaks of extended-spectrum beta-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital.

Authors:  A Pałucha; B Mikiewicz; W Hryniewicz; M Gniadkowski
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

6.  Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation.

Authors:  D A Schiappa; M K Hayden; M G Matushek; F N Hashemi; J Sullivan; K Y Smith; D Miyashiro; J P Quinn; R A Weinstein; G M Trenholme
Journal:  J Infect Dis       Date:  1996-09       Impact factor: 5.226

Review 7.  Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams.

Authors:  G A Jacoby
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

8.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Authors:  L B Rice; E C Eckstein; J DeVente; D M Shlaes
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

9.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

10.  Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors.

Authors:  G Vedel; A Belaaouaj; L Gilly; R Labia; A Philippon; P Névot; G Paul
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

View more
  79 in total

1.  The Role of Gram-Negative Bacteria in Urinary Tract Infections: Current Concepts and Therapeutic Options.

Authors:  Payam Behzadi; Edit Urbán; Mária Matuz; Ria Benkő; Márió Gajdács
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Emergence of community-acquired extended-spectrum beta-lactamase Escherichia coli (ESBLEC) in Honolulu: a case series of three individuals with community-acquired ESBLEC bacteriuria.

Authors:  Reid R Hoshide; Heath Chung; Jinichi Tokeshi
Journal:  Hawaii Med J       Date:  2011-09

3.  Increased resistance rate to ceftazidime among blood culture isolates of ESBL-producing Escherichia coli in a university-affiliated hospital of China.

Authors:  Xiao-Yan Yuan; Dong-Ying Yu; Xue-Hong Qu; Xin-Qiang Xiao; Bo Bi; Sheng-Bo Sun; Ai-Ying Chang; Qi-bo Zhang
Journal:  J Antibiot (Tokyo)       Date:  2015-09-30       Impact factor: 2.649

4.  Presence of multidrug-resistant enteric bacteria in dairy farm topsoil.

Authors:  J M Burgos; B A Ellington; M F Varela
Journal:  J Dairy Sci       Date:  2005-04       Impact factor: 4.034

5.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Patrick J Gavin; Mira T Suseno; Richard B Thomson; J Michael Gaydos; Carl L Pierson; Diane C Halstead; Jaber Aslanzadeh; Stephen Brecher; Coleman Rotstein; Stephen E Brossette; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  [Periprosthetic infections following total hip replacement with ESBL-forming bacteria: importance for clinical practice].

Authors:  M Haenle; A Podbielski; M Ellenrieder; R Skripitz; K Arndt; W Mittelmeier; R Bader; H Gollwitzer
Journal:  Orthopade       Date:  2011-06       Impact factor: 1.087

Review 7.  Bacterial resistance: a sensitive issue complexity of the challenge and containment strategy in Europe.

Authors:  W T M Jansen; J T van der Bruggen; J Verhoef; A C Fluit
Journal:  Drug Resist Updat       Date:  2006-06-27       Impact factor: 18.500

8.  Pollution impacts on bacterioplankton diversity in a tropical urban coastal lagoon system.

Authors:  Gigliola R B Salloto; Alexander M Cardoso; Felipe H Coutinho; Leonardo H Pinto; Ricardo P Vieira; Catia Chaia; Joyce L Lima; Rodolpho M Albano; Orlando B Martins; Maysa M Clementino
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  Screening of clinical, food, water and animal isolates of Escherichia coli for the presence of blaCTX-M extended spectrum beta-lactamase (ESBL) antibiotic resistance gene loci.

Authors:  John E Moore; Miyuki Watabe; B Cherie Millar; Anne Loughrey; Mark McCalmont; Colin E Goldsmith; J C Neville Heaney; Tom Buckley; Claire Egan; David A McDowell; M Ann S McMahon; James S G Dooley; Jiru Xu; Paul J Rooney
Journal:  Ulster Med J       Date:  2010-05

10.  Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp.

Authors:  Meeta Sharma; Sati Pathak; Preeti Srivastava
Journal:  J Clin Diagn Res       Date:  2013-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.